FastStroke, CT Perfusion 4D

The FastStroke and CT Perfusion 4D NeuroPackage is a software solution designed to enhance stroke diagnosis and assessment by providing advanced CT image analysis, including multiphase vascular visualization and quantitative perfusion mapping. It leverages deep learning for automated brain ventricle segmentation and offers a streamlined workflow with features like integrated applications and automated reporting to improve clinical efficiency.

NeuroPackage is a medical software solution combining FastStroke and CT Perfusion 4D applications to streamline CT stroke workflow. FastStroke is a CT image analysis tool designed to display head and neck vasculature from DICOM 3.0 CT scans at various enhancement time points, offering optimized, synchronized review formats and fusing multiphase vascular data into a single colorized view to aid in visualizing collateral vessels for stroke patient evaluation. CT Perfusion 4D analyzes dynamic CT perfusion images, post-contrast injection, to quantify parameters like regional blood flow, volume, mean transit time, and capillary permeability. These results, presented as parametric images, assist in assessing changes related to stroke or tumor angiogenesis and their treatment. The updated NeuroPackage integrates these two applications seamlessly within the FastStroke interface. Key technological advancements in the modified CT Perfusion 4D include the use of a deep learning convolutional neural network for automated brain ventricle segmentation, replacing a manual thresholding method. It also offers more flexibility in tissue classification by allowing users to select from multiple input parameters (Blood Volume, Blood Flow, TMax, MTT). Both FastStroke and CT Perfusion 4D now feature an automated email notification capability for distributing reports and results, aiming to improve workflow efficiency. Performance testing confirmed the deep learning algorithm's accuracy against expert annotations and overall software validation indicated no new safety or effectiveness concerns.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the quantitative improvement in brain ventricle segmentation accuracy and processing time achieved by the deep learning algorithm compared to the predicate's HU thresholding method?; How does the expanded selection of input parameters (Blood Volume, Blood Flow, TMax, MTT) for tissue classification in CT Perfusion 4D impact diagnostic interpretation or treatment planning for stroke and tumor angiogenesis compared to the previous restricted options?; What specific clinical scenarios or patient populations benefit most from the fused multiphase vascular information and collateral vessel visualization provided by FastStroke?; Are there any limitations or contraindications for using the deep learning-based ventricle segmentation, particularly in cases with atypical brain anatomy or significant pathology?; How does the automated email notification feature integrate with existing hospital Picture Archiving and Communication Systems (PACS) and electronic health record (EHR) systems, and what data security measures are in place for transmitting patient information?